Company Overview - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses [3] - The company's proprietary technology aims to inhibit CRAC channels to modulate immune responses and protect against tissue cell injury, potentially providing therapeutic benefits for life-threatening inflammatory and immunologic diseases without approved therapies [3] Product Development - CalciMedica's lead product candidate, Auxora™, has shown positive and consistent clinical results in multiple completed efficacy clinical trials [3] - The company has announced data for a Phase 2b trial (CARPO – NCT04681066) in patients with acute pancreatitis (AP) and systemic inflammatory response syndrome (SIRS) [3] - A Phase 2 trial (CARDEA – NCT04345614) has been completed in patients with COVID pneumonia [3] - Currently, a Phase 2 trial (KOURAGE – NCT06374797) is being conducted in patients with acute kidney disease (AKI) and associated acute hypoxemic respiratory failure (AHRF), with data expected in 2025 [3] - The company is also supporting an ongoing Phase 1/2 trial (CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT), with data also expected in 2025 [3] Upcoming Events - Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 8:00 a.m. ET [1] - A live webcast of the presentation will be available on CalciMedica's IR website, with a replay archived for 90 days [2]
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference